NCT04703686 2026-03-16Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells TherapyThe Lymphoma Academic Research OrganisationPhase 2 Completed67 enrolled
NCT05364424 2025-12-01A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Participants With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell LymphomaHoffmann-La RochePhase 1 Completed43 enrolled